Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Macrophages suppress T cell responses and arthritis development in mice by producing reactive oxygen species
Kyra A. Gelderman, … , Ragnar Mattsson, Rikard Holmdahl
Kyra A. Gelderman, … , Ragnar Mattsson, Rikard Holmdahl
Published October 1, 2007
Citation Information: J Clin Invest. 2007;117(10):3020-3028. https://doi.org/10.1172/JCI31935.
View: Text | PDF
Research Article Autoimmunity Article has an altmetric score of 3

Macrophages suppress T cell responses and arthritis development in mice by producing reactive oxygen species

  • Text
  • PDF
Abstract

Reduced capacity to produce ROS increases the severity of T cell–dependent arthritis in both mice and rats with polymorphisms in neutrophil cytosolic factor 1 (Ncf1) (p47phox). Since T cells cannot exert oxidative burst, we hypothesized that T cell responsiveness is downregulated by ROS produced by APCs. Macrophages have the highest burst capacity among APCs, so to study the effect of macrophage ROS on T cell activation, we developed transgenic mice expressing functional Ncf1 restricted to macrophages. Macrophage-restricted expression of functional Ncf1 restored arthritis resistance to the level of that of wild-type mice in a collagen-induced arthritis model but not in a T cell–independent anti-collagen antibody–induced arthritis model. T cell activation was downregulated and skewed toward Th2 in transgenic mice. In vitro, IL-2 production and T cell proliferation were suppressed by macrophage ROS, irrespective of T cell origin. IFN-γ production, however, was independent of macrophage ROS but dependent on T cell origin. These effects were antigen dependent but not restricted to collagen type II. In conclusion, macrophage-derived ROS play a role in T cell selection, maturation, and differentiation, and also a suppressive role in T cell activation, and thereby mediate protection against autoimmune diseases like arthritis.

Authors

Kyra A. Gelderman, Malin Hultqvist, Angela Pizzolla, Ming Zhao, Kutty Selva Nandakumar, Ragnar Mattsson, Rikard Holmdahl

×

Figure 3

ROS production by macrophages decreases arthritis severity.

Options: View larger image (or click on image) Download as PowerPoint
ROS production by macrophages decreases arthritis severity.
(A) Mice exp...
(A) Mice expressing functional Ncf1 on macrophages only (Ncf1*/*MN+: filled squares; n = 23) developed significantly less severe CIA as compared with Ncf1*/*MN– (open circles; n = 15) mice. After boost at day 35, a similar difference was also observed between Ncf1 heterozygous (+/*) mice with (n = 34) or without (n = 29) the transgene. No differences were observed in Ncf1 wild-type (+/+; n = 21 and 27) mice. All groups were included in each experiment. Mean ± SEM are shown of all mice, run in 2 different experiments with exactly the same setup, with the indicated total number of mice per group. #P < 0.05; †P < 0.005; ‡P < 0.0005. (B) Anti-CII IgG levels were determined at 10, 42, and 89 days after immunization and were significantly lower in transgene-positive (MN+) Ncf1*/* mice as compared with transgene-negative (MN–) Ncf1*/* mice. Sera from the CIA experiments as shown in A were used, with similar numbers of mice as indicated there. Means ± SEM are shown.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 2 patents
117 readers on Mendeley
1 readers on CiteULike
See more details